Effect of patient immunodeficiencies on the diagnostic performance of serological assays to detect Aspergillus-specific antibodies in chronic pulmonary aspergillosis.

"Declaration of competing interest These are our potential conflicts of interest. “Authors ESH, BAPW and CK declare no conflict of interests. MDR has received grant support from Gilead Sciences, Pfizer and MSD, and acts as a consultant and speaker for Gilead Sciences, Pfizer, Astellas and Schering-Plough. DWD and family hold Founder shares in F2G Ltd, a University of Manchester spin-out antifungal discovery company. He acts or has recently acted as a consultant to Scynexis, Pulmatrix, Pulmocide, Zambon, iCo Therapeutics, Mayne Pharma, Biosergen, and Fujifilm. In the last 3 years, he has been paid for talks on behalf of Hikma, Gilead, Merck, Mylan and Pfizer. He is a longstanding member of the Infectious Disease Society of America Aspergillosis Guidelines group, the European Society for Clinical Microbiology and Infectious Diseases Aspergillosis Guidelines group.”"

"Funding This work was primarily funded by the 10.13039/501100000265Medical Research Council Newton grant (MR/P017622/1) and the 10.13039/100014653NIHR Manchester Biomedical Research Centre. Bayu A.P. Wilopo is a PhD student supported by Indonesian Endowment Fund for Education (10.13039/501100014538LPDP) scholarship."